| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0002-9378(94)70414-7 |
| P698 | PubMed publication ID | 8296829 |
| P50 | author | Andrew Berchuck | Q114258102 |
| Robert C. Bast | Q37841724 | ||
| P2093 | author name string | Marks JR | |
| Boyd J | |||
| Kohler MF | |||
| Wiseman R | |||
| P2860 | cites work | Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer | Q72902089 |
| Mutations in the p53 gene occur in diverse human tumour types | Q28249770 | ||
| Genetic alterations during colorectal-tumor development | Q28281200 | ||
| p53 mutations in human cancers | Q28302973 | ||
| Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours | Q29547697 | ||
| The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 | Q29547773 | ||
| Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction | Q29618515 | ||
| Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms | Q29618586 | ||
| The p53 proto-oncogene can act as a suppressor of transformation | Q34440370 | ||
| TP53 tumor suppressor gene: a model for investigating human mutagenesis | Q35323631 | ||
| p53 gene mutations and protein accumulation in human ovarian cancer | Q36328863 | ||
| Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life | Q36782441 | ||
| Wild-type p53 is a cell cycle checkpoint determinant following irradiation | Q37152060 | ||
| The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines | Q37537138 | ||
| The p53 tumour suppressor gene | Q37751892 | ||
| Too many rodent carcinogens: mitogenesis increases mutagenesis | Q37848515 | ||
| Accumulation of p53 Tumor Suppressor Gene Protein: An Independent Marker of Prognosis in Breast Cancers | Q38487557 | ||
| Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation | Q41100590 | ||
| p53 gene mutations in human endometrial carcinoma | Q41108058 | ||
| Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours | Q41624924 | ||
| Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome | Q41816411 | ||
| Association of human papillomavirus types 16 and 18 E6 proteins with p53. | Q43701619 | ||
| Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. | Q43918911 | ||
| Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis | Q44449506 | ||
| Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease | Q44617061 | ||
| Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias | Q53478411 | ||
| High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomas. | Q54740689 | ||
| High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy | Q55352522 | ||
| Increased expression of mutant forms of p53 oncogene in primary lung cancer | Q58212568 | ||
| Mutagen test | Q59008997 | ||
| Human p53 gene localized to short arm of chromosome 17 | Q59074679 | ||
| p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry | Q63446378 | ||
| Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group | Q67979093 | ||
| Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA | Q68087656 | ||
| Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms | Q68097060 | ||
| P433 | issue | 1 Pt 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 246-252 | |
| P577 | publication date | 1994-01-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | American Journal of Obstetrics and Gynecology | Q4744256 |
| P1476 | title | The p53 tumor suppressor gene frequently is altered in gynecologic cancers | |
| P478 | volume | 170 |
| Q41035935 | A Detailed Immunohistochemical Analysis of a Large Series of Cervical and Vaginal Gastric-type Adenocarcinomas |
| Q33608825 | Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations |
| Q33431553 | Acquisition of a second mutation of the Tp53 alleles immediately precedes epithelial morphological transformation in ovarian tumorigenicity |
| Q40172885 | An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. |
| Q38067747 | Association Between p53 codon 72 Polymorphism and Cervical Cancer Risk Among Asians: a Huge Review and Meta-analysis |
| Q38184472 | Association of p53 codon 72 polymorphism with prostate cancer: an update meta-analysis |
| Q30437752 | Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study |
| Q74099804 | Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: Comparative molecular analysis of epithelial and mesenchymal components |
| Q43479718 | Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma |
| Q28073246 | Chemoresistance and targeted therapies in ovarian and endometrial cancers |
| Q35829935 | Chromosome 17 aneusomy detected by fluorescence in situ hybridization in vulvar squamous cell carcinomas and synchronous vulvar skin |
| Q45181400 | Clinicopathological features of ovarian carcinosarcomas: a single institution experience |
| Q71116149 | Comparison of benign and malignant endometrial lesions for their p53 state, using immunohistochemistry and temperature-gradient gel electrophoresis |
| Q59791850 | Defective Nuclear Lamina in Aneuploidy and Carcinogenesis |
| Q35221856 | Disabled-2 heterozygous mice are predisposed to endometrial and ovarian tumorigenesis and exhibit sex-biased embryonic lethality in a p53-null background |
| Q37215983 | Endometrial carcinoma: immunohistochemically detected proliferation index is a prognosticator of long-term outcome |
| Q41090745 | Establishment and Characterization of Cell Lines Derived from Uterine Malignant Mixed Müllerian Tumor |
| Q41090749 | Establishment and Characterization of Human Ovarian Carcinoma Cell Lines |
| Q35152940 | Evaluating the association between p53 codon 72 Arg>pro polymorphism and risk of ovary cancer: a meta-analysis |
| Q33284756 | Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas |
| Q40765172 | Expression of Cell-Cycle Mediators in Ovarian Cancer Cells after Transfection with p16INK4a, p21WAF1/Cip-1, and p53 |
| Q49067935 | Expression of cell cycle regulatory proteins (p53, pRb) in the human female genital tract |
| Q53664165 | Expression of cell cycle regulatory proteins in ovaries prophylactically removed from Jewish Ashkenazi BRCA1 and BRCA2 mutation carriers: correlation with histopathology |
| Q71102147 | Expression of cell regulatory proteins in ovarian borderline tumors |
| Q74008143 | Identification of p53 Mutations in Endometrial Adenocarcinoma by Polymerase Chain Reaction-Single-Strand Conformation Polymorphism |
| Q33901618 | Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature |
| Q86398003 | Immunologic markers of cancer progression and prognosis |
| Q35213250 | Immunologic principles and immunotherapeutic approaches in ovarian cancer |
| Q36806849 | Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome |
| Q62631293 | Impact of p53 arg72pro SNP on Breast Cancer Risk in North Indian Population |
| Q36135278 | Lack of mutation in tumour-suppressor gene p53 in gestational trophoblastic tumours |
| Q40866629 | Li-Fraumeni Syndrome and the Role of the p53 Tumor Suppressor Gene in Cancer Susceptibility |
| Q53394047 | Loss of Expression of the p16 Tumor Suppressor Gene Is More Frequent in Advanced Ovarian Cancers Lacking p53 Mutations |
| Q33489525 | Loss of GATA4 and GATA6 expression specifies ovarian cancer histological subtypes and precedes neoplastic transformation of ovarian surface epithelia |
| Q54660552 | Loss of heterozygosity and transcriptome analyses of a 1.2 Mb candidate ovarian cancer tumor suppressor locus region at 17q25.1-q25.2. |
| Q38469677 | Loss of heterozygosity of BRCA1, TP53 and TCRD markers analysed in sporadic endometrial cancer |
| Q35694610 | MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF. |
| Q38472762 | Malignant Mixed Müllerian Tumors of the Uterus: A Clinicopathologic, DNA Flow Cytometric, p53, and mdm-2 Analysis of 44 Cases |
| Q34035891 | Malignant mixed Mullerian tumors of the uterus: histopathological evaluation of cell cycle and apoptotic regulatory proteins |
| Q53432462 | Malignant transformation of mature cystic teratoma to squamous cell carcinoma involves altered expression of p53- and p16/Rb-dependent cell cycle regulator proteins |
| Q40989135 | Molecular basis of endometrial cancer |
| Q35065032 | Molecular pathogenesis and prognostic factors in endometrial carcinoma |
| Q38474312 | Molecular profile of advanced-stage transitional cell carcinoma of the ovary |
| Q24634248 | Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers |
| Q36201331 | Nuclear envelope structural defect underlies the main cause of aneuploidy in ovarian carcinogenesis |
| Q35552356 | Ovarian cancer and high-risk women—implications for prevention, screening, and early detection |
| Q51976333 | P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy |
| Q35983656 | Pathophysiological dynamics of human ovarian surface epithelial cells in epithelial ovarian carcinogenesis |
| Q85447231 | Prognostic Significance of Cell Cycle- and Invasion-Related Molecular Markers and Genomic Instability in Primary Carcinoma of the Vagina |
| Q79150763 | Prognostic Significance of p53 Mutation and p53 Overexpression in Advanced Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study |
| Q34086636 | Prognostic biomarkers in ovarian cancer |
| Q92444290 | Promising Terpenes as Natural Antagonists of Cancer: An In-Silico Approach |
| Q43605486 | Quantification of p53 in Epithelial Ovarian Cancer |
| Q73493307 | Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer |
| Q47369346 | Significantly decreased P27 expression in endometrial carcinoma compared to complex hyperplasia with atypia (correlation with p53 expression). |
| Q33940195 | Sodium arsenite and hyperthermia modulate cisplatin-DNA damage responses and enhance platinum accumulation in murine metastatic ovarian cancer xenograft after hyperthermic intraperitoneal chemotherapy (HIPEC) |
| Q58795530 | Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers |
| Q44827392 | Ten-year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma: dNA aneuploidy identifies high-risk cases among the so-called 'low-risk' patients with well and moderately differentiated tumors |
| Q37702059 | The association between the TP53 Arg72Pro polymorphism and colorectal cancer: An updated meta-analysis based on 32 studies |
| Q33622369 | The biology of ovarian cancer: new opportunities for translation |
| Q43545828 | The microsomal epoxide hydrolase Tyr113His polymorphism: association with risk of ovarian cancer. |
| Q37703901 | The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment |
| Q57306058 | The prohibitin 3′ untranslated region polymorphism is not associated with risk of ovarian cancer |
| Q35202999 | Treatment of ovarian cancer: new strategies |
| Q43546464 | Valproate, but not lamotrigine, induces ovarian morphological changes in Wistar rats |
| Q35180856 | Wild-type p53 controls cell motility and invasion by dual regulation of MET expression |
| Q43446793 | p53 overexpression in advanced-stage endometrial adenocarcinoma |
| Q30883366 | p53, estrogen and progesterone receptors in diagnostic curettage for endometrial adenocarcinoma and their correlation with morphological data and disease stage at hysterectomy |
Search more.